A report from the American Academy of Pediatrics (AAP) published in the journal Pediatrics cautions pregnant women and nursing mothers to avoid marijuana use due to possible adverse developmental effects to their baby. In a study reviewed for the report, short-term exposure to CBD was found to increase the permeability of the placental barrier, potentially placing the fetus at risk from certain substances.


Because it takes a significantly larger amount of hemp stalks to produce hemp oil, there is an increased risk of contamination of toxins contained within the plant. This is a result of hemp's strong bio-accumulator properties, where it pulls toxins from the soil it grows in. Many hemp oils are also known to lack the full spectrum of terpenes and other cannabinoids that are believed to act synergistically with the CBD, meaning that consumers receive less of a benefit. That being said, there are some brands that test rigorously to make sure that the CBD content, as well as the terpenes and other cannabinoids, are up to par. It's a good sign if they offer to provide a certificate of analysis, which will tell you what kind of compounds are in the hemp oil and in what concentrations
CBD may offer an option for treating different types of chronic pain. A study from the European Journal of Pain showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis. Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.
The World Economic Forum in Davos starts today and for the first time (medicinal) cannabis is part of the discussions being held there. Our founder and CEO Tjalling Erkelens will join these discussions for the rest of this week. His message will focus on the company's core values: separation of markets (medical vs recreational) and global harmonisation of laws and regulations in order ease patient access and allow for easier transfer of products around the world. ... See MoreSee Less
Receptra Naturals CBD products are derived from proprietary CBD rich hemp, grown on family owned and operated farms in Colorado using 100% organic farming practices on select organic soils without the use of pesticides or fungicides.  I got to know the folks at Receptra while dealing with Charlotte's Web Botanicals years back and continued to stay in contact when they left CW to form Receptra Naturals. 
‘There is intriguing preclinical and some clinical data supporting the use of cannabidiol (CBD) as an effective treatment for the management of anxiety disorders,’ says Dr Ware. ‘There are more than 30 preclinical studies that investigate the anxiolytic [anxiety-reducing] properties of CBD. These studies generally support the position that CBD has an effect on reducing anxiety behaviour.’
Everything you need to know about marijuana (cannabis) Marijuana, or cannabis, is the most commonly used illicit drug in the world. It alters the mood and affects nearly every organ in the body. With at least 120 active compounds, marijuana may have health benefits as well as risks. We describe these, addiction, and withdrawal. Learn more about cannabis here. Read now
It should also be noted that, because CBD oil is mostly unregulated, products may be incorrectly labeled. To that end, a study published in the Journal of the American Medical Association in 2017 found that nearly 70 percent of all CBD products sold online are mislabeled and that a number of products contain a significant amount of THC. Since THC can aggravate anxiety and make your heart beat faster than normal, it’s possible that using CBD oil that contains THC might make your anxiety worse.
Understanding CBD’s analgesic, or pain-relieving, interactions with the ECS can shed light on CBD’s other interactions and effects. Importantly, the ECS participates in our bodies’ pain processing, but when CBD is introduced to our ECS, it stops the body from absorbing a pain-regulating compound known as anandamide — one of our body’s’ own natural cannabinoid molecules. Inhibiting the absorption of this compound shunts excess quantities into the bloodstream that in turn reduces pain. One study has revealed that CBD targets alpha-3 (α3) glycine receptors to suppress chronic pain and inflammation associated with dysfunctional glycine receptors, which are an important target for pain processing in the spine. In both humans and animal models, CBD has been shown to have a variety of anti-inflammatory properties.
Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication.
Synthetic cannabinoids also pose a significant risk to users because the effects can be much more severe than those produced by marijuana. Some of the compounds in synthetic cannabinoids bind more strongly to brain receptors, which is why the effects could be more powerful and unpredictable. Moreover, synthetic cannabinoid products don’t always list every ingredient on the packaging label, so the effects of the product could be greater or different than expected.
Some medications are changed and broken down by the liver. Cannabidiol might decrease how quickly the liver breaks down some medications. In theory, using cannabidiol along with some medications that are broken down by the liver might increase the effects and side effects of some medications. Before using cannabidiol, talk to your healthcare provider if you take any medications that are changed by the liver.
Hash oils seized in the 1970s had a THC contents ranging from 10 to 30%. The oil available on the U.S. West Coast in 1974 averaged about 15% THC.[2] Samples seized across the United States by the Drug Enforcement Administration over an 18-year period (1980–1997) showed that THC content in hashish and hashish oil averaging 12.9% and 17.4%, respectively, did not show an increase over time.[4] The highest THC concentrations measured were 52.9% in hashish and 47.0% in hash oil.[5] Hash oils in use in the 2010s had THC concentrations as high as 90%[6][7] and other products achieving higher concentrations [8]
So far there isn’t a lot of data on the health risks of CBD. Initial studies suggest is it fairly well tolerated, and that it is not likely to cause dependence or abuse. The adverse events and side effects of CBD that have been reported appear to be related to interactions with prescription medications.  Since there is interest in CBD for treating various conditions, there is ongoing research into its safety profile, which may produce more information in the future.
Irie Hemp will be offering their products for sale in medical marijuana dispensaries in states such as California and Oregon, and as such, all products MUST undergo testing procedures required by the medical marijuana industry. Irie Hemp Company therefore will be adhering to a higher standard than most of the companies currently marketing and selling unregulated hemp based CBD online.

At sufficient doses (400-600 mg), CBD can alleviate situational anxiety, such as public speaking. Interestingly, cannabis cultivars, or strains, that are high in CBD and low in THC are better than other cultivars for alleviating depression. But when used over a long period of time, any kind of cannabis could make depression worse.  Although clinical trials in people haven’t yet been completed, there is very compelling “petri dish” evidence that CBD can reduce inflammation, for painful conditions such as Crohn’s disease, and fight some cancerous tumors. There is a massive amount of scientific research being done on CBD right now, and we are likely to see many medical breakthroughs in the next decade.
CBD oil may be of some benefit to those with addiction, suggests a review published in the journal Substance Abuse in 2015. In their analysis of 14 previously published studies, scientists determined that CBD may have therapeutic effects in people with opioid, cocaine, and/or psychostimulant addiction. They also found that CBD may be beneficial in the treatment of cannabis and tobacco addiction. There is some evidence that CBD may block or reduce the effects of THC on the mind.

THC and CBD are metabolized in the liver by a number of cytochrome P450 isoenzymes, including CYP2C9, CYP2C19, CYP2D6 and CYP3A4. They may be stored for as long as four weeks in the fatty tissues from which they are slowly released at sub-therapeutic levels back into the blood stream and metabolized via the renal and biliary systems. The main primary metabolite of CBD is 7-hydroxy-cannabidiol.
@gailb, where did you purchase the CBD. I also have been curious about the product, but there are lots of sellers on Amazon, but I hate to purchase a supplement that I don't know anything about the seller. Most of them you can find some pretty good lists of sellers that have good reputations. If you could give a brand name that you used and liked, I would appreciate it. If that is something that needs to be a PM, that will be fine. Thank you, Gary
CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically don’t respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and in some cases it was able to stop them altogether. Videos of the effects of CBD on these children and their seizures are readily available on the Internet for viewing, and they are quite striking. Recently the FDA approved the first ever cannabis-derived medicine for these conditions, Epidiolex, which contains CBD.

Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication. 
×